You just read:

REGENXBIO and Abeona Therapeutics Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector

News provided by

REGENXBIO Inc.

Nov 05, 2018, 07:00 ET